New Cetuximab Dosing Guidelines Approved for Colorectal Cancer and Head and Neck Cancer

The FDA has approved a new dosing regimen of 500 mg/m2 cetuximab (Erbitux®, Eli Lilly) for patients with KRAS wild-type epidermal growth factor receptor (EGFR)–expressing metastatic colorectal cancer (CRC) and patients with head and neck squamous cell carcinoma (HNSCC). This biweekly dosage regimen serves as an alternative to the existing weekly dosage regimen of cetuximab, whether on its own or combined with chemotherapy, and should be administered as a single 120-minute intravenous infusion ev...
Continue reading

Encorafenib/Cetuximab Approved: Metastatic Colorectal Cancer With BRAF V600E Mutations

​The FDA has now approved encorafenib (Braftovi®, Array BioPharma) in combination with cetuximab (Erbitux®, Lilly) for adults with previously treated metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test. "Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy," write Scott Kopetz, MD, PhD, FACP, and colleagues in their publica...
Continue reading

RNF43 Variation and Cetuximab Efficacy in Metastatic Colorectal Cancer: Francesca Battaglin, MD

​In metastatic colorectal cancer, there has been a concerted effort to identify biomarkers that can predict the efficacy of existing treatments and support the development of new targeted therapies. As part of these efforts, Francesca Battaglin, MD, and colleagues investigated the association between cetuximab efficacy and gene expression levels and genetic variants in the R-Spondin/RNF43 complex. For their analysis, the researchers used genomic DNA from blood samples of participants in the phas...
Continue reading

Palbociclib and Cetuximab Show Promise in Head and Neck Cancer

Many cases of head and neck squamous cell carcinoma (HNSCC) are caused by human papillomavirus (HPV); however, HNSCCs can be caused by a variety of factors, including p16INK4A inactivation (an inhibitor of cyclin-dependent kinase 4A) and overexpression of the oncogene cyclin D1. This results in the stimulation of cyclin-dependent kinase 4 and 6 (CDK4/6). Overexpression of cyclin D1 can also cause resistance to epidermal growth factor receptor (EGFR) inhibitors. To overcome this resistance, resea...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.